Chapter 6: Pulmonary and Anti-allergy Drugs

Pharmacology of a New Orally Active Antiallergic: Pyrido[1,2-a] Pyrimidine, ucb L140 (CHINOIN 1045) in Rats

“…Other compounds usually used in asthma therapy such as beta-adrenergic agonists, methylxanthine phosphodiesterase inhibitors and corticosteroids are not generally considered as 'prophylactic' agents [18,19], Although these compounds contributed greatly to asthma therapy, their side effects are not negligible, while on the other hand, the mode of administration of DSCG is relatively inconvenient. Thereby it seems that an orally active prophylactic antiallergic agent would be of a significant value.…”

Pathophysiology and Pharmacotherapy of Asthma: An Overview

“…In addition to cromolyn sodium, the pharmacological armamentarium for the management of asthma consists of several adrenergic bronchodilators (16) including epinephrine and isoproterenol and the new, (32-selective adrenergic drugs, theophylline and its several preparations, both systemic and inhaled corticosteroids, and anticholinergic agents such as atropine and its derivatives (11)(12)(13)(14)16,17). Concern as to potential side effects with some of these agents, as well as the relative inconvenience attendant to cromolyn sodium administration, suggests that an orally active prophylactic antiallergic agent with a rather broad therapeutic index would be of significant value.…”